Debt to Equity Ratio Chart

View Debt to Equity Ratio for AGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -1.458
March 31, 2026 -1.376
December 31, 2025 -1.235
September 30, 2025 -1.244
June 30, 2025 -1.136
March 31, 2025 -1.220
December 31, 2024 -1.322
September 30, 2024 -1.439
June 30, 2024 -1.706
March 31, 2024 -1.726
December 31, 2023 -2.184
September 30, 2023 -2.746
June 30, 2023 -3.801
March 31, 2023 -6.101
December 31, 2022 -6.037
September 30, 2022 -17.19
June 30, 2022 100.90
March 31, 2022 20.06
December 31, 2021 9.079
September 30, 2021 7.347
June 30, 2021 -1.338
March 31, 2021 -1.786
December 31, 2020 -1.642
September 30, 2020 -1.592
June 30, 2020 -1.392
Date Value
March 31, 2020 -1.496
December 31, 2019 -1.234
September 30, 2019 -1.353
June 30, 2019 -1.797
March 31, 2019 -2.806
December 31, 2018 -0.1043
September 30, 2018 -0.1054
June 30, 2018 -0.1219
March 31, 2018 -0.1188
December 31, 2017 -1.673
September 30, 2017 -2.168
June 30, 2017 -6.394
March 31, 2017 12.54
December 31, 2016 -2.866
September 30, 2016 -5.320
June 30, 2016 7.304
March 31, 2016 2.661
December 31, 2015 1.618
September 30, 2015 1.438
June 30, 2015 0.1311
March 31, 2015 0.2487
December 31, 2014 0.2618
September 30, 2014 0.1374
June 30, 2014 0.1289
March 31, 2014 0.1479

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Iovance Biotherapeutics, Inc. 0.0625
Novavax, Inc. -1.559
Fate Therapeutics, Inc. 0.4932
Amgen, Inc. 4.903
Anika Therapeutics, Inc. 0.1839

Debt to Equity Ratio Related Metrics